Publication
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerMalignant Endometrial Neoplasmcivic_curation1.00
- drugRidaforolimuscivic_curation1.00
- drugTemsirolimuscivic_curation1.00
- geneKRAScivic_curation1.00
- genePIK3CAcivic_curation1.00
- genePTENcivic_curation1.00
- variantKRAS Mutationcivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
- variantPTEN Losscivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24166148
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS Mutation1 | ||||||||
| Ridaforolimus + TemsirolimusSubstitutes | Malignant Endometrial NeoplasmCURATED_BROADER | Predictive | B | Does Not Support Sensitivity Response | 2 | accepted | EID89494 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. Mutations were found in 32 of 73 analyzed tum… (full text at CIViC) PMID 24166148 · Mackay et al., 2014 · Open in CIViC | civic |
| PIK3CA Mutation1 | ||||||||
| Ridaforolimus + TemsirolimusSubstitutes | Malignant Endometrial NeoplasmCURATED_BROADER | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID89294 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, inc… (full text at CIViC) PMID 24166148 · Mackay et al., 2014 · Open in CIViC | civic |
| PTEN Loss1 | ||||||||
| Ridaforolimus + TemsirolimusSubstitutes | Malignant Endometrial NeoplasmCURATED_BROADER | Predictive | B | Does Not Support Resistance | 3 | accepted | EID89394 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, inc… (full text at CIViC) PMID 24166148 · Mackay et al., 2014 · Open in CIViC | civic |